Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2018-04-18 Annual Report
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Annual Report 2017
Annual Report Classification · 1% confidence The document is titled 'ÅRSREDOVISNING 2017' (Annual Report 2017) and contains comprehensive sections typical of an annual report, including a table of contents, CEO statement, business strategy, clinical trial updates, and financial information. It is a full-length report (over 300,000 characters) detailing the company's performance and activities for the fiscal year 2017, fitting the definition of an Annual Report (10-K). FY 2017
2018-04-18 Swedish
Annual Report 2017
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2017' and contains comprehensive sections typical of a full annual report, including a CEO statement, business strategy, clinical trial summaries, and references to financial information. It is a substantial document (over 300,000 characters) and serves as the primary yearly report for the company, not an announcement or a summary. FY 2017
2018-04-18 English
ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is titled "ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)" which translates to "ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)". It details the date, location, registration procedures, agenda items (including election of board members, auditors, and remuneration), and specific proposals related to shareholder votes and incentive programs for directors. This content is characteristic of materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2018-04-17 Swedish
ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)" and details the notice, agenda, and proposed resolutions for this meeting, including items like election of the chairman, approval of financial statements, determination of director fees, and implementation of incentive programs. This content is characteristic of materials distributed for an Annual General Meeting (AGM). Although it mentions the annual report (item 8), the document itself is the notice and proposal document for the meeting, not the full 10-K or the standalone Audit Report. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length is substantial (over 45k characters), ruling out a simple Report Publication Announcement (RPA).
2018-04-17 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage by 'Stiftelsen Industrifonden' in 'Oncopeptides AB', specifically noting the 'Reason for major shareholding notification' and providing exact share quantities and resulting percentages (26.53999%). This structure is characteristic of a notification regarding a significant change in ownership interest, which aligns directly with the definition of Major Shareholding Notification (MRQ). The document is short and appears to be the official filing itself, not an announcement of a report.
2018-04-04 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release from Oncopeptides AB dated March 29, 2018. The core content announces a change in the total number of outstanding shares and votes due to a directed new share issue ('riktad nyemission'). This action directly impacts the company's capital structure and share count. Based on the provided definitions, this clearly falls under 'Capital/Financing Update' (CAP), as it details the result of a fundraising/capital structure change. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as the subject matter is highly specific to capital changes.
2018-03-29 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.